{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:53:49Z","timestamp":1793390029542,"version":"4.5.0"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["23725"],"award-info":[{"award-number":["23725"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117760","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T18:34:57Z","timestamp":1747247697000},"page":"117760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspective"],"prefix":"10.1016","volume":"294","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7228-0086","authenticated-orcid":false,"given":"Francesca","family":"Musumeci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Fasce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Falesiedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Oleari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Schenone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117760_bib1","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1016\/S1470-2045(20)30751-8","article-title":"Medical imaging and nuclear medicine: a lancet oncology commission","volume":"22","author":"Hricak","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117760_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23095023","article-title":"Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade","volume":"23","author":"Cri\u015fan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"9 19","key":"10.1016\/j.ejmech.2025.117760_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117760_bib4","series-title":"Handbook of Radiopharmaceuticals","first-page":"291","article-title":"Labeling with Gallium-68","author":"Burke","year":"2020"},{"key":"10.1016\/j.ejmech.2025.117760_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fmed.2022.812050","article-title":"Cold kit labeling: the future of 68Ga radiopharmaceuticals?","volume":"9","author":"Lepareur","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib6","article-title":"Gallium (III) complexes in cancer chemotherapy","volume":"2022","author":"Peng","year":"2022","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib7","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1515\/pac-2015-0703","article-title":"IUPAC periodic table of the elements and isotopes (IPTEI) for the education community (IUPAC technical report)","volume":"90","author":"Holden","year":"2018","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib8","first-page":"187","article-title":"Gallium-68 in medical imaging","volume":"9","author":"Martiniova","year":"2016","journal-title":"Curr. Rad."},{"key":"10.1016\/j.ejmech.2025.117760_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.4155\/ppa-2018-0016","article-title":"Gallium-68: methodology and novel radiotracers for positron emission tomography (2012-2017)","volume":"7","author":"Tanzey","year":"2018","journal-title":"Pharm Pat Anal"},{"key":"10.1016\/j.ejmech.2025.117760_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/jlcr.3371","article-title":"Detailed evaluation of different 68Ge\/68Ga generators: an attempt toward achieving efficient 68Ga radiopharmacy","volume":"59","author":"Chakravarty","year":"2016","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2025.117760_bib11","series-title":"Production of Long Lived Parent Radionuclides for Generators: 68Ge, 82Sr, 90Sr and 188W, IAEA Radioisotopes and Radiopharmaceuticals Series No. 2","year":"2010"},{"key":"10.1016\/j.ejmech.2025.117760_bib12","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.3390\/molecules200712913","article-title":"68Ga-Based radiopharmaceuticals: production and application relationship","volume":"20","author":"Velikyan","year":"2015","journal-title":"Molecules"},{"issue":"1 10","key":"10.1016\/j.ejmech.2025.117760_bib13","first-page":"1","article-title":"Development and long-term evaluation of a new 68Ge\/68Ga generator based on nano-SnO2 for PET imaging","volume":"10","author":"Romero","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.117760_bib16","first-page":"163","article-title":"The current status of the production and supply of Gallium-68","volume":"35","author":"Kumar","year":"2020","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.ejmech.2025.117760_bib18","article-title":"SNMMI image of the year 2022: PET\/CT biomarker predicts Post-MI cardiac remodeling","volume":"63","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib19","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/ERC-20-0360","article-title":"Somatostatin receptor radionuclide therapy in neuroendocrine tumors","volume":"28","author":"Haider","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2025.117760_bib20","first-page":"14","article-title":"[68Ga]Ga-PSMA-11: the first FDA-approved 68Ga-Radiopharmaceutical for PET imaging of prostate cancer","author":"Hennrich","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117760_bib21","doi-asserted-by":"crossref","first-page":"12004","DOI":"10.1021\/acs.chemrev.3c00456","article-title":"Theranostic nuclear medicine with Gallium-68, Lutetium-177, Copper-64\/67, Actinium-225, and Lead-212\/203 radionuclides","volume":"123","author":"Morgan","year":"2023","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib22","doi-asserted-by":"crossref","DOI":"10.1053\/j.semnuclmed.2024.06.001","article-title":"Expanding role for Gallium-68 PET imaging in oncology","volume":"54","author":"Kleynhans","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.semnuclmed.2022.08.005","article-title":"Gallium-68 labelled radiopharmaceuticals for imaging inflammatory disorders","volume":"53","author":"Vorster","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3390\/ph18030387","article-title":"Gallium-labeled PET radiopharmaceuticals in cardiovascular disease","volume":"18","author":"Bailly","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117760_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ph15050518","article-title":"Radiopharmaceutical labelling for lung ventilation\/perfusion PET\/CT imaging: a review of production and optimization processes for clinical use","volume":"15","author":"Blanc-B\u00e9guin","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117760_bib26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","article-title":"State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical Immuno-PET","volume":"32","author":"Chomet","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib27","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.addr.2008.04.006","article-title":"Bifunctional coupling agents for radiolabeling of biomolecules and target-specific delivery of metallic radionuclides","volume":"60","author":"Liu","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib28","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1039\/c0cs00199f","article-title":"The synthesis and application of polyamino polycarboxylic bifunctional chelating agents","volume":"40","author":"Lattuada","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib29","author":"Tsionou"},{"key":"10.1016\/j.ejmech.2025.117760_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0020-1693(00)86821-8","article-title":"Stabilities of the Fe(III), Ga(III) and In(III) chelates of N,N\u2032,N\u2033-Triazacyclononanetriacetic acid","volume":"181","author":"Clarke","year":"1991","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2025.117760_bib32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.nucmedbio.2014.09.009","article-title":"Comparison of DOTA and NODAGA as chelators for (64)Cu-labeled immunoconjugates","volume":"42","author":"Ghosh","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0020-1693(00)80229-7","article-title":"Stabilities of trivalent metal ion complexes of the tetraacetate derivatives of 12-, 13- and 14-membered tetraazamacrocycles","volume":"190","author":"Clarke","year":"1991","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2025.117760_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ph13030038","article-title":"[68Ga]Ga-DOTA-TOC: the first FDA-approved 68Ga-Radiopharmaceutical for PET imaging","volume":"13","author":"Hennrich","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117760_bib35","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/bc700307y","article-title":"Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules","volume":"19","author":"Ahlgren","year":"2008","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib36","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1002\/chem.201701508","article-title":"Equilibrium, kinetic and structural properties of Gallium(III) and some divalent metal complexes formed with the new DATAm and DATA5m ligands","volume":"23","author":"Farkas","year":"2017","journal-title":"Chemistry"},{"key":"10.1016\/j.ejmech.2025.117760_bib37","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1039\/c3ob40287h","article-title":"Conformational analysis and synthetic approaches to polydentate perhydro-diazepine ligands for the complexation of gallium(III)","volume":"11","author":"Parker","year":"2013","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib38","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cmdc.201500092","article-title":"Approaching \u201cKit-Type\u201d labelling with (68)ga: the DATA chelators","volume":"10","author":"Seemann","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117760_bib39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00259-019-04611-1","article-title":"Evaluation of [68Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [68Ga]Ga-DOTA-NOC PET\/CT","volume":"47","author":"Yadav","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/j.semnuclmed.2016.04.003","article-title":"Bifunctional Gallium-68 chelators: past, present, and future","volume":"46","author":"Spang","year":"2016","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/bc010074f","article-title":"NODAGATOC, a new chelator-coupled somatostatin analogue labeled with [67\/68Ga] and [111In] for SPECT, PET, and targeted therapeutic applications of somatostatin receptor (hsst2) expressing tumors","volume":"13","author":"Eisenwiener","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00259-008-0757-6","article-title":"68Ga- and 111In-labelled DOTA-RGD peptides for imaging of \u03b1v\u03b23 integrin expression","volume":"35","author":"Decristoforo","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib43","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1021\/bc800538s","article-title":"68Ga-labeling of biotin analogues and their characterization","volume":"20","author":"Blom","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/cmdc.201500092","article-title":"Approaching \u2018Kit-Type\u2019 labelling with 68Ga: the DATA chelators","volume":"10","author":"Seemann","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117760_bib45","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0020-1693(94)04012-5","article-title":"Stability of metal ion complexes of N,N\u2032-bis(2-hydroxybenzyl)ethylenediamine-N,N\u2032-diacetic acid","volume":"224","author":"Ma","year":"1994","journal-title":"Inorg. Chim. Acta."},{"key":"10.1016\/j.ejmech.2025.117760_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.nucmedbio.2010.02.001","article-title":"ScVEGF-PEG-HBED-CC and scVEGF-PEG-NOTA conjugates: comparison of easy-to-label recombinant proteins for [68Ga]PET imaging of VEGF receptors in angiogenic vasculature","volume":"37","author":"Eder","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib47","doi-asserted-by":"crossref","first-page":"37214","DOI":"10.1039\/C9RA07723E","article-title":"The effects of trace metal impurities on Ga-68-radiolabelling with a tris(3-hydroxy-1,6-dimethylpyridin-4-one) (THP) chelator","volume":"9","author":"Cusnir","year":"2019","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.117760_bib48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1021\/acs.bioconjchem.5b00335","article-title":"New tris(hydroxypyridinone) bifunctional chelators containing isothiocyanate groups provide a versatile platform for rapid one-step labeling and PET imaging with 68Ga3+","volume":"27","author":"Ma","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-022-00180-1","article-title":"Good practices for 68Ga radiopharmaceutical production","volume":"7","author":"Nelson","year":"2022","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.ejmech.2025.117760_bib50","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.xphs.2016.09.034","article-title":"If euhydric and isotonic do not work, what are acceptable pH and osmolality for parenteral drug dosage forms?","volume":"106","author":"Roethlisberger","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ejmech.2025.117760_bib51","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1021\/acs.bioconjchem.1c00010","article-title":"Recent breakthrough in 68Ga-Radiopharmaceuticals cold kits for convenient PET radiopharmacy","volume":"32","author":"Satpati","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib52","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.ejmech.2025.117760_bib53","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.ejmech.2025.117760_bib54","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2025.117760_bib55","author":"Reubi"},{"key":"10.1016\/j.ejmech.2025.117760_bib56","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","article-title":"Peptide receptors as molecular targets for cancer diagnosis and therapy","volume":"24","author":"Reubi","year":"2003","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib57","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163940","article-title":"Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms","volume":"20","author":"Gatto","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117760_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","article-title":"Gastroenteropancreatic neuroendocrine tumours","volume":"9","author":"Modlin","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.117760_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117760_bib60","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"Sms 201\u2013995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.117760_bib61","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199011013231805","article-title":"Somatostatin-receptor imaging in the localization of endocrine tumors","volume":"323","author":"Lamberts","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib62","first-page":"10N","article-title":"FDA grants orphan drug designation for 68Ga-DOTATOC","volume":"55","year":"2014","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib66","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2967\/jnumed.121.263768","article-title":"68Ga-DOTATATE prepared from cyclotron-produced 68Ga: an integrated solution from cyclotron vault to safety assessment and diagnostic efficacy in neuroendocrine cancer patients","volume":"64","author":"Tremblay","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib67","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s00259-007-0587-y","article-title":"68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors","volume":"35","author":"Pettinato","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib68","first-page":"228","article-title":"Safety and accuracy of 68Ga-DOTATOC PET\/CT in children and young adults with solid tumors","volume":"7","author":"Abongwa","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmech.2025.117760_bib69","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2025.117760_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25174012","article-title":"Overview of radiolabeled somatostatin analogs for cancer imaging and therapy","volume":"25","author":"Eychenne","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117760_bib73","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ijcard.2015.05.073","article-title":"Imaging of myocardial inflammation with somatostatin receptor based PET\/CT - a comparison to cardiac MRI","volume":"194","author":"Lapa","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117760_bib75","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-019-0516-7","article-title":"Instant kit preparation of 68Ga-radiopharmaceuticals via the hybrid chelator DATA: clinical translation of [68Ga]Ga-DATA-TOC","volume":"9","author":"Sinnes","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2025.117760_bib76","doi-asserted-by":"crossref","first-page":"16436","DOI":"10.1073\/pnas.0607761103","article-title":"Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors","volume":"103","author":"Ginj","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117760_bib77","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","article-title":"Somatostatin receptor antagonists for imaging and therapy","volume":"58","author":"Fani","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib80","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-021-00819-1","article-title":"A novel read methodology to evaluate the optimal dose of 68Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial","volume":"11","author":"Miller","year":"2021","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2025.117760_bib81","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117760_bib82","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1126\/science.7512751","article-title":"Requirement of vascular integrin alpha v beta 3 for angiogenesis","volume":"264","author":"Brooks","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117760_bib83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.nucmedbio.2013.12.003","article-title":"Comparison of two new angiogenesis PET tracers 68Ga-NODAGA-E[c(RGDyK)]2 and (64)Cu-NODAGA-E[c(RGDyK)]2; in vivo imaging studies in human xenograft tumors","volume":"41","author":"Oxboel","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib84","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2967\/jnumed.122.264383","article-title":"Prospective phase II trial of [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET\/CT imaging of integrin \u03b1v\u03b23 for prognostication in patients with neuroendocrine neoplasms","volume":"64","author":"Carlsen","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib85","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14728222.2016.1113260","article-title":"The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies","volume":"20","author":"Su","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2025.117760_bib86","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s000180050497","article-title":"The plasminogen activation system in tumor growth, invasion, and metastasis","volume":"57","author":"Andreasen","year":"2000","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117760_bib87","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2967\/jnumed.121.263177","article-title":"Prospective phase II trial of prognostication by 68Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: implications for uPAR-Targeted therapy","volume":"63","author":"Carlsen","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib88","doi-asserted-by":"crossref","first-page":"12157","DOI":"10.1021\/bi010662g","article-title":"Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation","volume":"40","author":"Ploug","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117760_bib89","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.nucmedbio.2011.10.011","article-title":"68Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers","volume":"39","author":"Persson","year":"2012","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib90","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1158\/2326-6066.CIR-14-0160","article-title":"Chemokines in cancer","volume":"2","author":"Chow","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ejmech.2025.117760_bib91","doi-asserted-by":"crossref","first-page":"27566","DOI":"10.18632\/oncotarget.4491","article-title":"Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy","volume":"6","author":"Kaemmerer","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117760_bib92","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2967\/jnumed.111.098798","article-title":"PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent","volume":"52","author":"Gourni","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib93","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1021\/acschembio.6b00074","article-title":"Conformational adaption May explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type I CDK inhibitor with kinetic selectivity for CDK2 and CDK9","volume":"11","author":"Ayaz","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib94","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.114.151647","article-title":"Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor","volume":"56","author":"Herrmann","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib95","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.7150\/thno.18754","article-title":"Imaging of chemokine receptor 4 expression in neuroendocrine tumors - a triple tracer comparative approach","volume":"7","author":"Werner","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117760_bib97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib98","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The latest developments in imaging of fibroblast activation protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib99","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib100","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based Theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib101","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib104","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1007\/s00259-021-05247-w","article-title":"The superiority of [68Ga]Ga-FAPI-04 over [18F]-FDG in a case of neuroendocrine tumour with hepatic metastasis","volume":"48","author":"Wang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib106","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2967\/jnumed.123.266183","article-title":"Design, preclinical evaluation, and clinical translation of 68 Ga-FAPI-LM3, a heterobivalent molecule for PET imaging of nasopharyngeal carcinoma","volume":"65","author":"Zhao","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-00243-0","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.117760_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13215360","article-title":"Molecular imaging in primary staging of prostate cancer patients: current aspects and future trends","volume":"13","author":"Manafi-Farid","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117760_bib109","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","article-title":"68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging","volume":"23","author":"Eder","year":"2012","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib110","unstructured":"Drug Approval Package: ILLUCCIX."},{"key":"10.1016\/j.ejmech.2025.117760_bib114","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/s41596-021-00662-7","article-title":"Synthesis of 68Ga-radiopharmaceuticals using both generator-derived and cyclotron-produced 68Ga as exemplified by [68Ga]Ga-PSMA-11 for prostate cancer PET imaging","volume":"17","author":"Rodnick","year":"2022","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejmech.2025.117760_bib116","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Benesov\u00e1","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.nucmedbio.2017.12.007","article-title":"Synthesis and evaluation of a novel urea-based 68Ga-complex for imaging PSMA binding in tumor","volume":"59","author":"Zha","year":"2018","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib119","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s11307-022-01720-6","article-title":"Preliminary evaluation of 68Ga-P16-093, a PET radiotracer targeting prostate-specific membrane antigen in prostate cancer","volume":"24","author":"Lee","year":"2022","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib121","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2967\/jnumed.117.191882","article-title":"68Ga-THP-PSMA: a PET imaging agent for prostate cancer offering rapid, room-temperature, 1-Step kit-based radiolabeling","volume":"58","author":"Young","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib122","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s11307-018-1160-8","article-title":"Imaging characteristics and first experience of [68Ga]THP-PSMA, a novel probe for rapid kit-based Ga-68 labeling and PET imaging: comparative analysis with [68Ga]PSMA I&T","volume":"20","author":"Derlin","year":"2018","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2025.117760_bib124","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2967\/jnumed.120.250738","article-title":"177Lu-Labeled albumin-binder-conjugated PSMA-targeting agents with extremely high tumor uptake and enhanced tumor-to-kidney absorbed dose ratio","volume":"62","author":"Kuo","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib125","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.7150\/thno.76571","article-title":"What a difference a methylene makes: replacing Glu with Asp or Aad in the lys-urea-glu pharmacophore of PSMA-targeting radioligands to reduce kidney and salivary gland uptake","volume":"12","author":"Kuo","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2025.117760_bib126","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2967\/jnumed.117.198192","article-title":"Will GRPR compete with PSMA as a target in prostate cancer?","volume":"58","author":"Iagaru","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib127","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/pr.107.07108","article-title":"International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states","volume":"60","author":"Jensen","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.117760_bib128","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"Kahkonen","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117760_bib129","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of 68Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [18F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejmech.2025.117760_bib131","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1021\/bc300659k","article-title":"Synthesis and characterization of a high-affinity NOTA-Conjugated bombesin antagonist for GRPR-targeted tumor imaging","volume":"24","author":"Varasteh","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.117760_bib132","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","article-title":"Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours","volume":"38","author":"Mansi","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib133","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.117.198929","article-title":"PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate cancer patients","volume":"59","author":"Zhang","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib135","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-025-01198-7","article-title":"68Ga-NOTA-RM26 PET\/CT in the evaluation of glioma: a pilot prospective study","volume":"15","author":"Li","year":"2025","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2025.117760_bib136","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.124.267810","article-title":"Head-to-Head comparison of [68Ga]Ga-NOTA-RM26 and [18F]FDG PET\/CT in patients with gastrointestinal stromal tumors: a prospective study","volume":"66","author":"Wang","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib137","first-page":"583","article-title":"[68Ga]NeoBomb1, a new potent GRPR-antagonist for PET imaging - preclinical and first clinical evaluation in prostate cancer","volume":"57","author":"Nock","year":"2016","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib138","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for Theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib140","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2967\/jnumed.121.263507","article-title":"Radiotracers to address unmet clinical needs in cardiovascular imaging, part 2: inflammation, fibrosis, thrombosis, calcification, and amyloidosis imaging","volume":"63","author":"Stendahl","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib141","series-title":"Glioblastoma","first-page":"155","article-title":"PET imaging in glioblastoma: use in clinical practice","author":"Verger","year":"2017"},{"key":"10.1016\/j.ejmech.2025.117760_bib142","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3389\/fonc.2020.01633","article-title":"Clinical significance of somatostatin receptor (SSTR) 2 in meningioma","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117760_bib143","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3390\/cancers11121853","article-title":"Molecular imaging in pediatric brain tumors","volume":"11","author":"Chiaravalloti","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117760_bib144","first-page":"228","article-title":"Safety and accuracy of 68Ga-DOTATOC PET\/CT in children and young adults with solid tumors","volume":"7","author":"Abongwa","year":"2017","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejmech.2025.117760_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106535","article-title":"Breast cancer: biology, biomarkers, and treatments","volume":"84","author":"Barzaman","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejmech.2025.117760_bib148","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.2967\/jnumed.119.236000","article-title":"Initial clinical results of a novel Immuno-PET theranostic probe in human epidermal growth factor receptor 2-Negative breast cancer","volume":"61","author":"Rousseau","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib149","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/bjc.2013.376","article-title":"Development of an imaging-guided CEA-Pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results","volume":"109","author":"Schoffelen","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117760_bib150","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1535-7163.MCT-09-0862","article-title":"Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts","volume":"9","author":"Schoffelen","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117760_bib151","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.107.046185","article-title":"Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting","volume":"49","author":"Goldenberg","year":"2008","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1144817","article-title":"Molecular imaging of HER2 receptor: targeting HER2 for imaging and therapy in nuclear medicine","volume":"10","author":"Miladinova","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2025.117760_bib154","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib155","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2967\/jnumed.109.073346","article-title":"Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold","volume":"51","author":"Ahlgren","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib156","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s00259-024-06999-x","article-title":"Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga -NODAGA-SNA006","volume":"52","author":"Wang","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib157","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1007\/s00259-022-05903-9","article-title":"Pilot study of a novel nanobody 68 Ga-NODAGA-SNA006 for instant PET imaging of CD8+ T cells","volume":"49","author":"Wang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2025.117760_bib159","article-title":"68Ga-MY6349 PET\/CT imaging to assess Trop2 expression in multiple types of cancer","volume":"135","author":"Chen","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117760_bib160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12951-023-02183-9","article-title":"TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer","volume":"21","author":"Xu","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2025.117760_bib162","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1148\/rg.2020200021","article-title":"Theranostics in nuclear medicine: emerging and Re-emerging integrated imaging and therapies in the era of precision oncology","volume":"40","author":"Marin","year":"2020","journal-title":"Radiographics"},{"key":"10.1016\/j.ejmech.2025.117760_bib163","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.2967\/jnumed.117.190801","article-title":"An overview of PET radiochemistry, part 2: radiometals","volume":"59","author":"Brandt","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2025.117760_bib166","first-page":"255","article-title":"Radiotheranostics in oncology: making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.117760_bib169","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020315","article-title":"PSMA-targeted nanotheranostics for imaging and radiotherapy of prostate cancer","volume":"16","author":"Meher","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117760_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.646387","article-title":"PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging","volume":"11","author":"Holzgreve","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117760_bib171","doi-asserted-by":"crossref","first-page":"7911","DOI":"10.7150\/thno.56639","article-title":"A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma","volume":"11","author":"Bolcaen","year":"2021","journal-title":"Theranostics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:10:41Z","timestamp":1765602641000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":136,"alternative-id":["S0223523425005252"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117760","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Approaching Gallium-68 radiopharmaceuticals for tumor diagnosis: a Medicinal Chemist's perspective","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117760","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117760"}}